Spektus Pharma Inc., a Canadian specialty pharmaceutical company, and GEBRO Holding GmbH, an Austrian pharmaceutical company, have entered into a global commercialisation partnership for ActraFlex, a twice-daily extended-release formulation of tramadol and paracetamol developed for pain management.

ActraFlex combines Spektus Pharma's patented AmyloFlex drug-delivery platform with GEBRO's established Diliban tramadol/paracetamol product. The formulation is designed to provide sustained drug release through an extended-release delivery profile, allowing twice-daily dosing.

Under the agreement, GEBRO will be responsible for commercialisation and supply across Europe and selected Rest of World (RoW) markets, with Spain serving as the key market, supported by the existing regulatory and commercial presence of Diliban. Spektus will oversee commercialisation and supply across North America, South America and selected RoW markets through its network of regional commercialisation partners.

The partnership aims to combine GEBRO's experience and established market presence in pain management with Spektus' proprietary drug-delivery technology and international commercialisation network. Both companies will work towards introducing ActraFlex across multiple international markets through their respective regional operations.

Commenting on the partnership, Zarvaan Merchant, CEO of Spektus Pharma, said the agreement demonstrated the potential of the company's AmyloFlex technology to develop differentiated specialty medicines using established pharmaceutical products. He added that the existing commercial presence of Diliban in Europe, combined with Spektus' network, could support ActraFlex's expansion across the Americas and selected markets in Africa and Asia.

Christian Kollenz, Managing Director of GEBRO Holding, said the company's experience in pain management and established presence with Diliban in Europe, together with Spektus' international commercialisation network, could support ActraFlex's growth across global markets.

The agreement establishes a global commercialisation framework under which both companies will lead the regulatory and commercial introduction of ActraFlex in their respective territories. The initiative will be supported by a common product platform and a shared international strategy.